Company intelligence / Profile preview
BioXcel Therapeutics, Inc.
New Haven, Connecticut, United States of Americabioxceltherapeutics.com ↗
- Ownership
- Public · BTAI
- Employees
- ~74
- Development stage
- Commercial
01
Overview
IGALMI (dexmedetomidine) sublingual film is FDA-approved for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company is advancing SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or schizophrenia, and developing plans for TRANQUILITY In-Care Phase 3 trial for agitation associated with Alzheimer's dementia. BXCL701 completed a Phase 2 clinical trial in combination with pembrolizumab in metastatic castration-resistant prostate cancer.
- Therapeutic areas
- OncologyPsychiatryNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Beyond the preview
Go deeper on BioXcel Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioXcel Therapeutics, Inc..